Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.

@article{KleineTebbe2006SafetyOA,
  title={Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.},
  author={Joerg Kleine-Tebbe and Mette C Ribel and Dr. Dietmar A. Herold},
  journal={Allergy},
  year={2006},
  volume={61 2},
  pages={181-4}
}
BACKGROUND Sublingual treatment of grass pollen induced rhinoconjunctivitis might provide easier access to specific immunotherapy (SIT) and minimize the risk of serious adverse events (AEs) compared to subcutaneous SIT. AIM OF THE STUDY To identify a safe dose range for once-daily administration of a grass allergen tablet in participants with grass pollen induced seasonal rhinoconjunctivitis. METHODS A randomized, double blind, placebo-controlled Phase I trial was conducted outside the… CONTINUE READING